Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. In this transcript, the company is running clinical trials for COMP360, a psychedelic treatment. They discuss site initiations, patient demand, and commercial preparation. The key is whether they convey that each new instance (e.g., each new site, each new contract, each new program) is individually bigger, broader, or longer than before. Looking at the transcript: They talk about Phase III trials COMP005 and COMP006. They mention site initiations, but no mention of increasing size of individual sites or contracts. They discuss the growth of esketamine (Spravato) sales, but that's a different product. They mention the August financing, but that's a financing deal, not a business engagement of the same kind. They talk about pre-commercial work and infrastructure, but no explicit statement that new sites are larger or that each new engagement is bigger. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." There is no such description. Management does not say that new sites are bigger, that new contracts are larger, or that the scope of each new program is expanding. They mention patient demand is strong, but that's about volume, not unit size. They also mention that they are adding sites, but not that each site is larger. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.